<*dv_3*>Endocardial Solutions Reports Third Quarter Earnings Results: Sales up 88%, EnSite Catheter Revenues Up 101% Over Q3'00

October 22, 2001
<*dv_2*>MINNEAPOLIS / ST.PAUL -- Endocardial Solutions, Inc. (Nasdaq: ECSI) today reported net sales for the third quarter ended September 30, 2001 of $5,818,000, compared with revenues of $3,097,000 for the same period of 2000. The net loss for the third quarter was $1,994,000 or $.13 per share, compared with a net loss of $2,791,000, or $.23 per share, for the same period of 2000. Year-to-date sales are $15,998,000, compared to $10,194,000 for the same period last year, reflecting an increase of 57%.

"Once again we had a record-breaking quarter across the board," said Jim Bullock, President and Chief Executive Officer. "Most impressive is the continued forward momentum in EnSite system sales. This quarter we sold 20 EnSite systems, and we are now poised to significantly overachieve our goal of having 200 systems sold by the end of the year!"

"Additionally, we were very excited to receive FDA approval on our Precision™ software. This is the most significant improvement in the EnSite 3000® System since its introduction in June of 1999. As announced earlier this month, Precision™ dramatically improves the chamber geometry, navigational capabilities, and arrhythmia analysis," stated Bullock.

"Our business models continue to mature in the U.S. and we are encouraged by the response from our customers regarding our direct European marketing and sales progress," concluded Bullock.

<*dv_4*>The U.S. Food and Drug Administration cleared the EnSite 3000® System for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart during the second quarter 1999.

Based in St. Paul, Minnesota, Endocardial Solutions (www.endocardial.com) develops, manufactures and markets technology for diagnostic mapping of complex arrhythmias (abnormally rapid heartbeats caused by irregular electrical activity in the heart). The EnSite 3000® System provides a 3D graphical display of the heart’s electrical activity.

Earnings Conference Call: October 23, 2001 beginning at 9:30 (CST)

1-877-272-5391

<*dv_5*>Moderator: Jim Bullock, President and CEO

<*dv_1*> The discussion above is based on preliminary financial results, which are subject to further review and adjustment, and contains forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995, including statements regarding gross margins, operating expenses and revenue expectations, that involve a number of risks and uncertainties. A number of factors should be considered in conjunction with these forward-looking statements. These factors are set forth in the cautionary statements included in Exhibit 99 to Endocardial Solutions’ Form 10K/A for the year ended December 31, 2000, filed with the Securities and Exchange Commission. Endocardial Solutions cautions investors and others to review the statements set forth in that report and that other factors may prove to be important in affecting the business and results of operations of Endocardial Solutions.

Contacts:

<*dv_0*>Jim Bullock, President and CEO, Endocardial Solutions (651) 523-6928 jbullock@endocardial.com

Brenda Gutzke, Investor Relations (651) 523-6959 bgutzke@endocardial.com